Folic acid and reduction of the cardiovascular risk from iperomicisteinemia in the patients subordinates to liver transplant. - ND
- Conditions
- Reduction of the overomocisteinemieMedDRA version: 9.1Level: LLTClassification code 10051286Term: Hyperhomocysteinaemia
- Registration Number
- EUCTR2005-005178-55-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Patients subordinates to transplant of liver from at least 6 months with advanced levels of total plasmatic omocisteine over to 15 mmol/L, decided to accept to join voluntarily to the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Patients subordinates to transplant of liver from at least 6 months that they do not accept to join to the voluntary study and patients who have one contraindication to the supplement with folic acid
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method